National Award for Prof. Suman Chakraborty on Teachers Day 2023

Teaching is much more than just imparting knowledge, it is an inspiring change. Learning is more than absorbing facts, it is acquiring understanding. When we recall our own education, we remember the teachers not methods and techniques. The belief of a teacher on his/her student can make them achieve wonders. Teachers are the root of an education system and can change lives with just the right mix of chalk and challenges. Teaching is the profession that teaches us all the other professions. On this momentous occasion of Teachers Day 2023, Prof. Suman Chakraborty, a professor in the Mechanical Engineering Department at the IIT Kharagpur has been selected for the National Awards to Teachers 2023.

If you can simplify the technology, you don’t need a doctor or a highly qualified technician to work on the technology; even an Asha Health Worker or a similar front line health worker can use it with minimal training,’ said Prof. Suman Chakraborty, a professor in the Mechanical Engineering Department at the IIT Kharagpur, who has been selected for the National Awards to Teachers 2023 by the Ministry of Education, Department of Higher Education, Government of India.

Your research has been on developing devices that would help rural healthcare. Is there any particular incident that caught your attention to this often neglected area?

If you look at the journey of any researcher, you will see there are certain things which happen by chance, rather without much planning. You develop certain insights from experience and that direct you to one particular direction. That is the case with me too. I worked on micro fluidics and its applications on healthcare, but not particularly focusing on rural healthcare. Though at IIT Kharagpur where I work has a township, it is basically located in a rural area. There is a railway station here and if you go beyond the railway station, the scenario is totally different. It is like any other rural area you see in India. It is difficult not to notice the huge contrast and difference between the kind of facilities and access to facilities we have at IIT and a place that is just a kilometre away from IIT. People there do not have either affordability or accessibility to healthcare, or a combination of these two.

It was a disturbing scenario…

Definitely. It still is disturbing. The focus of our work has always been on medical diagnostics, but when I noticed this disturbing disparity, we shifted our focus to the under-served sections of our society. That means, the technologies we use now can be used in the field and not in labs where you have air-conditioning, refrigeration and high-end machines. We have tried to solve the problem in some way, but we are yet to come out with a robust solution that will solve the problem completely. Yes, we could solve it in such a way that it is better than what it was earlier. If you look at the technological developments in healthcare, they are done with the assumption that everybody can afford it. You have these high-end labs and diagnostic centres manned by qualified technicians and doctors in big hospitals which are not accessible to everyone. Even if they are accessible, not many can afford them.

Reports say 80% of doctors in India work in urban areas. Do you think technology alone can solve a lot of healthcare deficiencies in rural areas?

Technology alone cannot solve the problem entirely, but most of it. If you can simplify the technology, you don’t need a doctor or a highly qualified technician to work on the technology; even an Asha health worker or a similar front line health worker can use it with minimal training.

Does that mean you were simplifying the technology so that they can use it in the rural areas?

Yes. That’s where the challenge comes; simplifying the technology without compromising on the performance. When you simplify technology, there is always a danger of compromising on accuracy. So, what we were developing had to be simple yet accurate and also cost-effective. Initially, you cannot go for simplification of technology as as you may miss some scientific components. It is a two-step process for us. First, we develop the technology in the lab so that we will know the nitty-gritties of the technology. Then, we move on to simplifying it.

Can you give us an example? For example, you have developed a device to check the haemoglobin level of individuals in the field and not in the lab…

There is a classical test used in all the labs which can be manual, semi-automated or fully automated. What we did was, we tried to understand the principle and then implement the principle on a piece of paper. We use just one drop of blood from the finger onto to a strip of paper and get the result within a minute. The amount of reagent we use also is very less, thus reducing the cost. What we do is, design the paper in such a way that the same principle we use in labs works on the paper too, that is the same chemistry and same reaction.

Is it an ordinary paper?

It’s a filter paper. When you compare the results of the test done on the paper and also in a lab, you will see that the results are more or less the same.

Is it for the initial diagnosis that these kits are used?

You can treat it as good as any standard lab test. The next step after the test is, take a picture of the colour of the blood to check the level of haemoglobin. For that, we keep the strip in a box, and with the help of a smart phone camera, the picture of the image is taken. Then the analysis of the colour of the blood is done by the app that is formatted in the phone. The image analysis and interpretation is done automatically by the phone and the person taking the test doesn’t have to do anything. Remember we do not expect the person, taking the test, for example as Asha worker to know anything about the technology. When the result comes on the app interface, it will be accessible to any doctor who is sitting in a big city. Like you said, 80% of the doctors are located in the urban areas. After looking into the test result and the patient’s history, the doctor can immediately give the first level of recommendation. For example, if the haemoglobin level is extremely low, and the patient requires an immediate blood transfusion, the caregiver can take him to a place where the patient can be administered blood. If it is only mild anaemia, the doctor may prescribe medicine or dietary changes.

Prof. Suman Chakraborty and researchers at IIT-Kharagpur are developing a technology to source electricity from clothes drying in open space

Was this the first device you developed?

The first one was to test the glucose level in the blood. The glucometer that is generally used by people is quite expensive for a person living in the rural area. We also developed another device to check the creatinine level as kidney is the first organ that gets affected by uncontrolled diabetes. Then, we have a device to check the lipid profile. We have this belief that only people in the urban areas suffer from high cholesterol. No, those in the rural areas also are affected. The diseases which we previously thought to be associated with urbanisation are there in the rural areas also because of the life style changes. Diabetes affects rural India more because they lack facilities to check the sugar level periodically. The idea behind all our inventions are, there is a need for early detection of diseases.

Do you use the same paper strip for all the tests, for example for haemoglobin, creatinine and glucose?

The paper is the same but we use different reagents for different tests.

Can we say almost all the common diseases are tackled at the preliminary stage through your devices?

Yes, you can say that. We have devices for these basic tests. Then we also have devices to diagnose infectious diseases like flu with which we can diagnose TB also which is a major disease in rural India. We use molecular diagnostics for infectious diseases which is one of the most difficult diagnostic technologies. But we have created a portable device which is an alternative to the RT-PCR machine. This machine we developed during the covid time is named COVIRAP. This machine is a 1ft x 1ft x 1ft box and it can perform the test like an RT-PCR machine, and the test results can be known within 40-45 minutes. Though we developed it for covid tests during the covid period, subsequently we use it influenza test. Now, we use it to detect TB. The advantage is, you can use the same device to do different tests by using different strips of paper with different reagents.

You have also developed a device to detect oral cancer…

If you notice, the device we spoke about earlier require body fluids to test. The device we developed to detect oral cancer does not require any body fluid; it is done through imaging. Though there are several reasons for oral cancer, majority of the patients are tobacco or gutka users, and they belong to the group who do not have access to early detection or care. If detected early, any ulceration in the mouth can be prevented from becoming cancer by changing their lifestyle. A large number of people could be saved if it is detected early. What we have developed is a device which looks like a torch with a thermal camera with which we can take the picture of any ulceration inside the mouth.The image we grab from inside the mouth is temperature at different points. The algorithm we have developed will convert the temperature into showing the blood flow in the area. If there is cancer in an area, new blood vessels grow (angiogenesis). There will be a significant change in the blood flow pattern in an area when there is cancer or pre-cancer.

You have used AI (Artificial Intelligence) in all your devices. How important is AI in developing devices like these?

AI is very important particularly in the healthcare space as there is a lot of difference between one person to another. Every human being is different. Health issues are also very personalised and you see variations in every person. In the normal conditions itself, even the physical appearance of say, the inside of the mouth of one person is different from another person. With the help of AI, we can predict the individual variations more accurately.

Do you consider what you are doing as part of your responsibility towards society?

Of course. Social responsibility can be addressed in different ways by different people. This is the way people working science and technology can impart their responsibility to society. What we are doing is not even 10% of what is needed. We have only introduced the technology; it has to be a part of the healthcare system and not present in an isolated manner here and there. And it cannot be done by the efforts of one or two individuals; it has to be a national movement and part of the entire system.

Some Major Awards & Accolades :

  • The Shanti Swarup Bhatnagar Award in 2013.
  • The J C Bose Fellowship in 2018.
  • The G D Birla Award in 2021.
  • The Infosys Prize in 2022.
  • National Award for Teachers 2023.

Media Coverage:

The Bengal Post Anandabazar Patrika 

Interview : Courtesy Rediff.Com

Edited By : Poulami Mondal, Digital & Creative Media Executive (Creative Writer)
Email: poulami.mondal@iitkgp.ac.in, media@iitkgp.ac.in, Ph. No.: +91-3222-282007

Follow us on: Facebook – IIT Kharagpur; Twitter – @IITKgp;  Instagram – @iit.kgp; LinkedIn – Indian Institute of Technology
For news visit: https://kgpchronicle.iitkgp.ac.in/

Global Launch of COVIRAP – Nucleic acid-based Point-of-Care Diagnostic Device for COVID-19 and beyond

Highlights

  • A generic step-wise isothermal nucleic acid-based testing technology for the rapid diagnostics of pathogenic infections including but not limited to SARS-CoV-2 in individuals.

  • Nasal Swab/ Saliva to result from integration in about 45 minutes in a highly affordable pre-programmable portable device developed by the team, without requiring any separate facility for RNA extraction.

  • Kit supplemented with a free smartphone app to facilitate unambiguous results interpretation and automated dissemination to the patients. The test may be performed by unskilled personnel outside the controlled lab with no intermediate manual intervention between sample loading and result dissemination.

  • Patents filed in the India, USA, several other countries, and the foreign filing license has been granted recently.

  • The unique trade-off between the high scientific standards of advanced molecular diagnostics with the elegance of common rapid tests for underserved community care.

IIT Kharagpur has successfully commercialized its flagship healthcare product – COVIRAP – the novel diagnostic technology for infectious diseases including COVID-19 and beyond. The product developed by lead researchers Professor Suman Chakraborty, Dr. Arindam Mondal and their research group has been licensed for commercialization to the Rapid Diagnostic Group of Companies, India and Bramerton Holdings LLC, USA. 

Bramerton Holdings has signed a record deal for securing global rights for commercially disseminating the COVIRAP technology developed at IIT Kharagpur in various geographical locations outside the territory of the Indian subcontinent.  Rapid Diagnostic has also initiated adapting the COVIRAP technology platform for COVID-19 and tuberculosis, in collaboration with IIT Kharagpur.

The research team has now developed a more advanced version of COVIRAP using a step-wise isothermal nucleic acid testing technology for the rapid diagnostics of pathogenic infections including SARS-CoV-2 in individuals. The COVID-19 diagnostic test can be conducted directly from human swab samples in the portable device developed by the team, without requiring any separate facility for RNA extraction. The results can be made available within 45 minutes of obtaining the patient sample. The kit has also been also supplemented with a free smartphone app to facilitate unambiguous results interpretation and automated dissemination to the patients. 

Recognizing the impact of the COVIRAP technology in meeting the long-standing demands of high-quality community-level testing, IIT Kharagpur has further initiated the procedure of deploying this product for on-campus use to detect possible novel coronavirus infection.

“The above move has taken place at a critical juncture when the recent spurt in COVID-19 infection, commonly known as the second wave, has been threatening to spread more rapidly than ever before. Moreover, the commercialization of COVIRAP will initiate complete indigenization and availability of a large range of affordable healthcare products in the Indian market as well as deep trenches of a large global market that is literally starving for the need of such technology. COVIRAP promises its reach to the grass-root level in catering to the needs of the last person of the society,” opined Director Prof. V K Tewari.

For use of the test, the nasal, as well as oral swab samples, are diluted in a solution and tested in the portable device by mixing with reagents that are supplied in a pre-mixed form. The test runs automatically in the device without intermediate manual intervention.

“We have conducted field trials for running the tests with the help of unskilled personnel outside controlled laboratory ambiance, with no compromise in quality of the test outcome. The entire sample-to-result procedure may be conducted in the portable device, virtually anywhere and with minimal training thus making the process of testing more effective for community-level screening and early detection of any emerging infection outbreak. This may act as a key to arrest community level spreading of the infection,” remarked Prof. Suman Chakraborty.

Nucleic acid-based point-of-care tests such as COVIRAP usher great promises as viable alternatives for rapid testing of pathogenic infections at low cost in resource-limited settings.

“The COVIRAP test overcomes several potential bottlenecks faced by similar other tests in the past, for instance, poor performance outside highly controlled laboratory and lack of simple, affordable, yet generic and universal instrument that may be used for home-based testing and community healthcare for a wide variety of infectious and non-infectious diseases,” he explained.

Patents centered around this innovation have been filed in the India, USA, several other countries, in the name of IIT Kharagpur. The foreign filing license has been granted recently. Commercialization and use in the USA and Europe under the Emergency Use Authorization (EUA) process are currently underway. Both the Rapid Diagnostic Group in India and Bramerton Holdings in the USA, in association with IIT Kharagpur, have already identified the key resources towards establishing the reagent supply chain, kit and device manufacturing in entirety under a ‘Make in India’ initiative with complete import substitution. In addition to licensing COVIRAP to these companies, the inventors at IIT Kharagpur will receive further support via industrial consultancy project mode for further advancement of the product. 

The envisaged trade-off between the high scientific standards of advanced molecular diagnostics with the elegance of common rapid tests appears to be the future of infectious disease detection and management. A platform technology capable to be inclusive of all such disease detections where nucleic acid-based tests may be deployed, COVIRAP is not just a one-time solution targeted specifically to COVID-19 but will remain imperative in global disease management overall years to come.


For more information contact:

Research & Product: Prof. Suman Chakraborty, suman@mech.iitkgp.ac.in; Media: media@iitkgp.ac.in; VeenaNxt: info@VeenaNxt.com

Follow IIT Kharagpur on Facebook/Twitter: @IITKgp     Instagram: @iit.kgp


About IIT Kharagpur: Indian Institute of Technology Kharagpur is a higher educational institute known globally for its graduate output and affordable technology innovations. Set up in 1951 in a detention camp as an Institute of National Importance, the Institute is ranked among the top five in India and has been awarded Institute of Eminence by the Govt. of India in 2019. The key areas of research of IIT Kharagpur are Affordable Healthcare Technologies, Advanced Manufacturing, Advanced Transportation, Precision Agriculture and Food Technology, Cyberphysical Systems, Ecology & Environment, Mining, Water Resources and Architecture. The Institute is engaged in several international and national mission projects and ranks significantly in research output including 50-100 IPR filed annually and about 2000 research publications in top journals and conferences. At present, the Institute has about 750 full-time equivalent faculty members, more than 14000 students and over 70000 Alumni. For more information visit: www.iitkgp.ac.in

About COVIRAP Commercial Partners:

Rapid Diagnostic Group of Companies: Founded by Dr. Bharat Jindal, a medical doctor by profession, the companies were established in 1995 with the sole aim of providing quality and leading-edge products and services to the Indian Healthcare ecosystem. By now, they have established an extensive national network of 22 offices and 4,000 distributors, enabling outreach to customers at under-resourced locations where the infrastructure of high-end diagnostic tests remains non-existent. In response to the pandemic situation, they came into the production of COVID IgG ELISA kits with a joint venture of ICMR/NIV, Rapid tests, PPE kits, Masks and few more products which can help the Nation. Boosted by their own manufacturing facility of diagnostic tests based in Delhi, they envision bringing the COVIRAP technology to the Indian Market at the earliest. As a pioneer in the industry, their mission is to provide timely, high-quality diagnostic kits, diagnostic instruments, point of care and critical care instruments at an affordable price. They have also initiated adapting the COVIRAP technology platform for TB diagnostics, in collaboration with IIT Kharagpur.

Bramerton Holdings: Bramerton Holdings is a subsidiary of Riverfort Global Capital (ww.riverfort.com). The Riverfort Group comprises a London-based investment advisor regulated by the UK Financial Conduct Authority and a number of regulated investment funds and investment companies. In addition, the Riverfort group is an investor in the Sure Vally Ventures (SVV) venture capital fund which invests in early-stage technology companies and includes both private sector and governmental investors. The Riverfort Group and its founders have arranged and advised the funding of over 100 companies deploying over 500 million USD in capital. Bramerton Holdings is launching the special purpose vehicle for the global development and distribution of the COVIRAP technology via its subsidiary called VeenaNxt Limited. [Contact at info@VeenaNxt.com]

The  Bramerton Holdings leadership team includes Chairman Brian Kinane,  (MBA London & Columbia Business Schools) and BA (Computer Science, Trinity College Dublin) having more than 12 years investment fund management experience and 15 years entrepreneurial, corporate & operational experience across global technology giants; Gytis Martinkus, Managing Director & CFO, an experienced financial professional having qualified long-term association with the KPMG;  Subhendu K Misra, Managing Director US Markets, MBA (Columbia Business School, USA) and BS and MS (in Computer Science from Rensselaer Polytechnic Institute, USA), having over 20 years of experience at the intersection of life sciences, technology, and innovation, involving the top global pharmaceutical and medical devices companies across the US, Europe, and Japan; and  Mark Wheeler, Chief Legal Officer, a qualified practicing solicitor holding, by training LLB in law (University of Bristol) and LPC (University of Law, Guildford branch), having over 10 years of  experience as a qualified solicitor, and named as a key individual in small cap capital markets and up to £ 50m mergers and acquisitions transactions in the Legal 500, 2020 edition.The VeenaNxt Limited board of directors includes Richard Morgan and Peter Bains as a strategic advisor. Richard Morgan is on the VeenaNxt board of directors. Richard co-founded Celgene in 1987 and was on the board for 20 years, serving as Chairman and CEO before recruiting a new CEO.  He remained on the board for a further 10 years, serving on the Executive Committee and chairing the Compensation Committee until his retirement in 2008.  He was the Chairman of Quidel Corp, a NASDAQ listed company, and Polarean. Richard was also a Managing Partner at Wolfensohn Partners LP which followed 15 years at Schroders plc, then a leading British merchant bank. In 1982 he completed the Advanced Management Program at the Harvard Business School. Peter Bains is a strategic advisor to VeenaNxt. Peter is currently CBO and Executive Director of Mina Therapeutics, a privately held UK biotech company as well as Non Executive Director of Mereo BioPharma Group plc, a NASDAQ listed company and Indivior, a FTSE listed company. Peter was the Chief Executive Officer of Syngene International, which he successfully took public on the Mumbai Exchanges in 2015. Peter has over three decades of experience in the biotech and pharmaceutical industry, which included a 23-year career at GlaxoSmithKline, among other roles he was also a member of various GSK teams with strategic, operations, marketing, and business development responsibilities and a Member of the Board of Directors of GSK India.  He also served as the Representative Executive Officer and Chief Executive Officer of Sosei Group Corporation, a Tokyo listed biotech company. Their team profile for the exclusive launch of COVIRAP in the global market is boosted further by executive scientist Dr. Gopal Pattanayak, Staff Scientist at the University of Chicago in the life sciences space, as well as Dr. Ajaya K. Mohanty, an internationally recognized technology professional having played a leading role in developing private and public sector partnerships in scientific research, education and IT, and having advised and consulted on the National Supercomputing Mission and (Digital) Infrastructure in India and recipient of  an award bestowed by the President of India in 2017.